CRISPR-Cas9 Gene Editing: A Promising Frontier in Revolutionizing Alzheimer’s Disease Management

Abstract

Alzheimer’s disease (AD) is a globally devastating neurodegenerative disorder with a significant burden on public health. Currently, the pathophysiology of AD remains uncertain. Meanwhile, conventional pharmacological treatments for AD accomplished with limited efficacy and undesirable side effects necessitate the exploration of novel therapeutic approaches. This paper highlights the potential of clustered regularly interspaced short palindromic repeats-associated proteins nine systems (CRISPR-Cas9) as a promising approach to cure AD by examining its applications in genome editing and mechanism of action on specific AD-related genes. In addition to targeted therapeutic options for either familial or sporadic AD, the review also emphasizes the importance of utilizing in vivo and in vitro AD experimental models to evaluate the efficacy and safety of CRISPR-Cas9 interventions. The significance of this research lies in its potential to revolutionize AD management and serve as a valuable reference for future studies. However, unresolved issues, such as the complexity of on-target effects and the need for improved delivery efficiency, underscore areas for future ongoing investigation and development in the field of AD therapeutics.